MURA

Mural Oncology's Strategic Shift: Mural Oncology plc has decided to discontinue the clinical development of its lead drug candidate, Nemvaleukin, due to insufficient efficacy in trials and will explore strategic alternatives to maximize shareholder value, including potential sale or merger options.

Market Reaction and Financial Status: Following the announcement, Mural's shares surged by over 147%, while the company plans to reduce its workforce by approximately 90% and has retained Lucid Capital Markets as a financial advisor; it currently holds about $144.4 million in cash and equivalents.

U.S. Stock Market Performance: U.S. stocks saw gains with the Dow Jones up 0.17%, NASDAQ rising 0.39%, and S&P 500 increasing by 0.35%. Citigroup reported better-than-expected earnings, boosting investor confidence.

Global Market Trends: European and Asian markets also experienced positive movements, with significant gains in indices such as the eurozone's STOXX 600 and Japan's Nikkei 225, while commodity prices showed mixed results.

Market Performance: U.S. stocks rose this morning, with the Nasdaq gaining approximately 100 points, while Bank of America reported better-than-expected earnings for Q1, boosting financial shares by 1.3%.

Global Market Trends: European and Asian markets also saw gains, with the eurozone's STOXX 600 up 1.5% and Japan's Nikkei 225 rising 0.84%, alongside mixed commodity prices where oil and gold increased slightly.

Discontinuation of Clinical Development: Mural Oncology has announced the discontinuation of all clinical development for nemvaleukin alfa following unsatisfactory results from phase 2 and phase 3 trials, leading to a significant workforce reduction of approximately 90%.

Exploration of Strategic Alternatives: With $144.4 million in cash as of December 31, 2024, Mural plans to explore strategic alternatives to maximize shareholder value, including potential mergers or acquisitions, while currently not being in active discussions with any offerors.

NASDAQ 100 Pre-Market Overview: The NASDAQ 100 is down -35.03 to 18,760.99 with a total pre-market volume of 177,396,069 shares traded, featuring active stocks like Mural Oncology (+1.05) and Boeing (-5.78).

Stock Performance Highlights: Notable stock movements include Direxion Daily TSLA Bull 2X Shares showing a significant increase from its 52-week low, while Bank of America has had positive earnings forecast revisions for the upcoming quarter.

U.S. Stock Market Performance: U.S. stocks showed mixed results with the Nasdaq gaining 0.29% while the Dow fell slightly by 0.06%. Notable stock movements included Tenon Medical's shares surging 287% and Mural Oncology's shares dropping 58%.

Economic Indicators: Sales of new single-family homes rose by 1.8% in February, despite a previous decline, while home price indices showed slight increases year-over-year, indicating ongoing fluctuations in the housing market.

Power Solutions International Earnings Surge: Power Solutions International, Inc. reported a significant increase in fourth-quarter earnings, rising to $1.01 per share from 36 cents the previous year, leading to a 9.8% jump in its stock price during pre-market trading.

Stock Movements in Pre-Market Trading: Several stocks experienced notable changes in pre-market trading, with Tenon Medical, Inc. soaring by 91.2% after FDA clearance, while Integrated Media Technology Limited saw a sharp decline of 30% following a previous surge.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Upcoming Clinical Trials: Mural Oncology is set to report interim overall survival analysis for the ARTISTRY-7 trial in platinum-resistant ovarian cancer by late Q1/early Q2 2025, alongside top-line data from the ARTISTRY-6 trial in mucosal melanoma expected in Q2 2025.

Financial Performance: The company reported a net loss of $34.3 million for Q4 2024, down from $59.5 million in Q4 2023, and has extended its cash runway into Q1 2026 through operational efficiencies.

Analyst Ratings Initiations: Several Wall Street analysts have initiated coverage on various companies, including Vital Farms with an Outperform rating and a price target of $52, Scilex Holding with a Buy rating and a target of $22, Palladyne AI Corp with a Buy rating and a target of $15, Sagimet Biosciences with a Buy rating and a target of $42, and Mural Oncology with a Buy rating and a target of $16.

Current Stock Prices: The closing stock prices for these companies were significantly lower than their respective price targets, with Vital Farms at $43.14, Scilex Holding at $0.4404, Palladyne AI at $9.86, Sagimet Biosciences at $4.20, and Mural Oncology at $3.95.

Upcoming Clinical Trials: Mural Oncology is set to release interim data for its ARTISTRY-7 trial in platinum-resistant ovarian cancer by late Q1/early Q2 2025, and top-line results for the ARTISTRY-6 trial in mucosal melanoma in Q2 2025, with additional readouts planned throughout 2025.

New Development Candidates: The company has nominated two new candidates, MURA-8518 and MURA-7012, targeting IL-18 and IL-12 respectively, with an IND submission for MURA-8518 expected in Q4 2025, while extending its cash runway into Q1 2026 through operational efficiencies.

Employee Stock Options Granted: Mural Oncology granted stock options and restricted stock units to four new employees, totaling 26,300 ordinary shares in stock options and 13,200 in restricted stock units, as part of their 2024 Inducement Stock Option and Incentive Plan.

Company Overview: Mural Oncology is focused on developing novel cytokine-based immunotherapies for cancer treatment, with its lead candidate, nemvaleukin, currently undergoing trials for mucosal melanoma and platinum-resistant ovarian cancer.

Economic Outlook Post-Election: Following Trump's election victory, market analysts predict favorable economic growth due to slowing inflation and a lower-rate policy from the Federal Reserve, alongside expectations of a deregulatory approach that historically boosts the economy.

Stock Recommendations: Analysts from Raymond James highlight two biopharmaceutical companies, Mural Oncology and Disc Medicine, as strong investment opportunities, with Mural potentially offering a 440% upside and Disc Medicine showing a 70% upside based on their promising drug pipelines and recent regulatory progress.

Clinical Trial Results: The ARTISTRY-1 trial demonstrated that nemvaleukin, an engineered fusion protein, was well tolerated and showed promising anti-tumor activity in heavily pretreated patients with advanced solid tumors, particularly in platinum-resistant ovarian cancer and mucosal melanoma.

Future Prospects: Mural Oncology is advancing two potentially registrational trials for nemvaleukin, with results expected in early to mid-2025, aiming to address significant unmet needs in cancer treatment.

Real-time Intelligence: Benzinga Pro offers traders the fastest and most accurate stock market intelligence, helping them make informed decisions daily.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and alerts generated by Benzinga reporters.

Employee Stock Options Granted: Mural Oncology granted stock options and restricted stock units to five new employees, totaling 23,500 shares in stock options and 12,500 shares in restricted stock, as part of their 2024 Inducement Stock Option and Incentive Plan.

Company Overview: Mural Oncology is focused on developing cytokine-based immunotherapies for cancer treatment, with its lead candidate, nemvaleukin, currently undergoing trials for mucosal melanoma and platinum-resistant ovarian cancer.

Coverage Initiation and Price Forecast: HC Wainwright & Co. has initiated coverage of Mural Oncology with a Buy recommendation, projecting a 258.38% upside based on an average one-year price target of $13.26/share from its current price of $3.70/share.

Fund Sentiment and Shareholder Activity: There has been a decrease in institutional ownership by 22.62% over the last quarter, with notable changes in share allocations among major shareholders, indicating mixed sentiment towards Mural Oncology's stock.

Upcoming Presentations: Mural Oncology will present three posters at the 39th Annual Meeting of the Society for Immunotherapy of Cancer, showcasing data from their ARTISTRY-3 study on nemvaleukin and preclinical research on IL-18 and IL-12.

Innovative Therapies: The company is developing engineered cytokine therapies to enhance cancer treatment efficacy while minimizing side effects, with plans to nominate development candidates for their IL-18 and IL-12 programs by the end of this year.

Analyst Ratings Changes: Several Wall Street analysts have initiated coverage on various companies, including Tandem Diabetes Care with a Neutral rating and a price target of $46, Mural Oncology with a Strong Buy rating and a price target of $18, and ASP Isotopes with a Buy rating and a price target of $4.5.

Stock Performance: Following these ratings, Tandem Diabetes Care shares fell by 1.7%, while Mural Oncology and ASP Isotopes saw gains of 2.6% and 11.1%, respectively, indicating varied market reactions to the analyst outlooks.

Clinical Trials Update: Mural Oncology is conducting late-stage trials for nemvaleukin in platinum-resistant ovarian cancer and mucosal melanoma, with key data expected in early 2025. The ARTISTRY-7 trial has completed enrollment of 456 patients, while the ARTISTRY-6 trial for mucosal melanoma has enrolled 92 patients.

Future Developments: Mural plans to submit an IND for its IL-18 program by Q4 2025 and aims to provide further insights into their clinical study designs during a virtual Investor Day, highlighting the potential of their therapies to address unmet medical needs in oncology.